What Makes Icon PLC (ICLR) an Investment Bet?
In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as ICON Public Limited Company (NASDAQ:ICLR). Headquartered in Dublin, Ireland, ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization. The one-month return of ICON Public Limited Company (NASDAQ:ICLR) was -13.11%, and its shares lost 50.23% of their value over the last 52 weeks. On April 9, 2025, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $155.49 per share with a market capitalization of $12.567 billion.
GreensKeeper Asset Management stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2025 investor letter:
"We made one new purchase in the quarter: ICON Public Limited Company (NASDAQ:ICLR). ICLR is a leading contract research organization (CRO) based in Ireland that manages clinical trials for pharmaceutical and biotechnology companies worldwide. Despite some uncertainty driven by recent personnel changes at the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), we believe that new drugs and medical devices will continue to be developed, and scientific progress will continue. New drugs require rigorous clinical testing before reaching the market. As a leading CRO, ICLR will capture its fair share of clinical trials once the dust settles."
A laboratory setting with a team of scientists working on a clinical trial.
ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 46 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the fourth quarter which was 48 in the previous quarter. ICON Public Limited Company's (NASDAQ:ICLR) fourth quarter revenue was $2.04 billion, represents a year-on-year decrease of 1.2%. While we acknowledge the potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
We covered ICON Public Limited Company (NASDAQ:ICLR) in another article, where we shared LVS Advisory's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Apple (NASDAQ:AAPL) Reports Strong Q2
iPhone and iPad maker Apple (NASDAQ:AAPL) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 9.6% year on year to $94.04 billion. Its GAAP profit of $1.57 per share was 10.1% above analysts' consensus estimates. Is now the time to buy Apple? Find out in our full research report. Apple (AAPL) Q2 CY2025 Highlights: Revenue: $94.04 billion vs analyst estimates of $89.54 billion (5% beat) Operating Profit (GAAP): $28.2 billion vs analyst estimates of $25.86 billion (9.1% beat) EPS (GAAP): $1.57 vs analyst estimates of $1.43 (10.1% beat) Products Revenue: $66.61 billion vs analyst estimates of $62.76 billion (6.1% beat) Services Revenue: $27.42 billion vs analyst estimates of $26.81 billion (2.3% beat) Gross Margin: 46.5%, in line with the same quarter last year Operating Margin: 30%, in line with the same quarter last year Free Cash Flow Margin: 26%, down from 31.1% in the same quarter last year Market Capitalization: $3.12 trillion 'Today Apple is proud to report a June quarter revenue record with double-digit growth in iPhone, Mac and Services and growth around the world, in every geographic segment,' said Tim Cook, Apple's CEO. Revenue Growth Apple (with its installed base of 2 billion+ devices) proves that huge, scaled companies can still grow. The company's revenue base of $273.9 billion five years ago has increased to $408.6 billion in the last year, translating into a decent 8.3% annualized growth rate. In light of its big tech peers, however, Apple's growth trailed Amazon (15.8%), Alphabet (17.5%), and Microsoft (14.5%) over the same period. This is an important consideration because investors often use the comparisons as a starting point for their valuations. When adjusting for these benchmarks, we think Apple's price is fair. We at StockStory emphasize long-term growth, but for big tech companies, a half-decade historical view may miss emerging trends in AI. Apple's recent performance shows its demand has slowed as its annualized revenue growth of 3.2% over the last two years was below its five-year trend. This quarter, Apple reported year-on-year revenue growth of 9.6%, and its $94.04 billion of revenue exceeded Wall Street's estimates by 5%. Looking ahead, sell-side This projection illustrates the market sees some success for its newer AI-enabling Apple Intelligence products. However, its anticipated growth is still a far cry from its heyday in the 2010s. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Products: Steve Jobs's Legacy Apple's Products segment includes everything from its flagship iPhone, iPad, and MacBook computers to AirPods and Apple Watch. We are closely monitoring whether the GenAI-powered Apple Intelligence, which was released in September 2024 but has limited interoperability with older devices, can spur an upgrade cycle for the company. Products sales are by far the biggest chunk of Apple's revenue at 74.2%, and they grew by 6.4% annually over the last five years, slower than total revenue. Recently, sales have also decelerated, as revenue was flat over the last two years. Apple could really use that upgrade cycle right about now. This quarter, Products sales were up 8.2% year on year, topping Wall Street's estimates by 6.1%. Holding aside expectations, the recently improved rate of change shows that more customers are upgrading their devices than before. We'll be watching to see if Apple Intelligence and iOS 18 can accelerate this trend. Wall Street seems to believe it won't move the needle. Key Takeaways from Apple's Q2 Results We were impressed by how significantly Apple blew past analysts' revenue expectations this quarter. We were also happy its revenue narrowly outperformed Wall Street's estimates, as Products and Services all beat. Zooming out, we think this was a solid print. The stock traded up 2.4% to $212.58 immediately after reporting. Apple may have had a good quarter, but does that mean you should invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Trump's lawyers encounter some courtroom skepticism as they defend tariffs that start Friday
Small business importers and the US Justice Department clashed Thursday over whether President Trump has the authority to impose his "Liberation Day" tariffs just hours before those duties were scheduled to take effect for countries around the world. The confrontation took place in Washington, D.C. before a panel of 12 judges at the Circuit Court of Appeals for the Federal Circuit, and it did not produce an immediate ruling. But it did reveal that some judges have some skepticism of the Justice Department's arguments that the president can unilaterally impose wide-ranging, global tariffs by invoking a law enacted in 1977 to protect the US from international threats, while others found support for the claim. Read more: 5 ways to tariff-proof your finances That law, known as 'IEEPA' — the International Economic Emergency Powers Act — authorizes the president to 'regulate' international commerce after declaring a national emergency. The panel — composed of eight judges appointed by former Democratic presidents and four appointed by Republican presidents — spent considerable time asking the lawyers what Congress meant when it wrote in IEEPA that presidents have authority to 'regulate importation.' 'IEEPA doesn't even say 'tariffs.' It doesn't even mention it,' one judge said. 'What does 'regulation of importation' mean?' another judge asked. And 'If 'regulate' doesn't cover tariffs, what does it cover?' A lawyer for one of 12 states joining the small businesses in their challenge of Trump's tariffs, Brian Simmonds Marshall, said he thought the phrase was meant to permit the president to order quotas that limit the number of imported goods, and potentially for the president to order import licensing requirements and fees. But 'the one thing that I think it excludes for sure is tariffs,' Simmonds Marshall added. But Trump's Justice Department Assistant Attorney General Brett Shumate said that IEEPA doesn't have such limits and that Congress would have understood that when it wrote the law. And while IEEPA offers the president broad power, Shumate said that power is not unlimited because it is available only during a national emergency, and Congress can step in and overrule the president. 'The primary rule is for Congress to check the president if there is an abuse of the IEEPA tariff authority,' Shumate said. Trump and Nixon The judges also questioned if a Nixon-era case that addressed IEEPA's predecessor law, known as the Trading with the Enemy Act (TWEA), put limits on what a president can do under IEEPA. Trump's team has been citing that 1970s case as proof that the president's global tariffs should be allowed to stand in court. Roughly five decades ago, 10% duties unilaterally imposed by the former President Nixon as part of a set of economic measures dubbed the "Nixon shock" were challenged in court in much the same way as Trump's 2025 tariffs have been. A Japanese zipper-making business called Yoshida International sued, saying Nixon lacked the power to set the 10% tariff on foreign goods under three different laws that the government gave as justification: the Tariff Act, the Trade Expansion Act, and the Trading with the Enemy Act (TWEA). The most controversial justification was the TWEA, a predecessor law to the 1977 act that Trump cited this year as a basis for his multiple tariffs. A US Customs Court initially sided with the zipper importer, holding that none of the three laws was adequate authority for the duty. Yet on appeal, Nixon's tariffs were upheld. The court that upheld the tariffs reasoned that "neither need nor national emergency" justified Nixon's tariff because Congress had not delegated such power and because the authority was "not inherent" in his office, but that TWEA carved out enough power to regulate importation during an economic emergency. One of the judges hearing the Trump case on Thursday cited that 1970s case and said, 'It seems pretty clear to me that Yoshida is telling us that 'No, the president doesn't have the authority to rewrite the Tariff Schedule.' In this case, that's what the president is trying to do.' Read more: The latest news and updates on Trump's tariffs A lawyer for the challengers to Trump's duties argued that by adopting IEEPA in 1977, Congress ratified the high court's holding in Yoshida, which he said allowed the president to impose 'modest, bounded, temporary tariffs' but did not sanction unbounded, permanent duties. 'Good luck in America's big case' The lawyers and judges also sparred over whether the president's declared national emergency met IEEPA's requirements of unusual and extraordinary, and Trump found some support during this discussion. One judge agreed the president did meet these requirements by identifying underlying causes contributing to the threat, including trade deficits, tariff barriers, and a lack of reciprocity in US trading relationships. That, this judge said, contributed to a spike in the US's trade deficit and atrophied domestic production capacity, including in defense industrial bases. 'How does that not constitute what the president is expressly saying is an extraordinary threat?' the judge asked the challengers. But another judge countered, 'How can a trade deficit be an extraordinary and unusual threat when we've had trade deficits for decades?' Lawyers for the administration argued that the deficit becomes extraordinary and unusual once it reaches a point where it threatens the resources that are foundational to US national security. Trump was clearly paying attention to the courtroom developments. 'To all of my great lawyers who have fought so hard to save our Country, good luck in America's big case today,' Trump wrote Thursday morning on Truth Social. 'If our Country was not able to protect itself by using TARIFFS AGAINST TARIFFS, WE WOULD BE 'DEAD,' WITH NO CHANCE OF SURVIVAL OR SUCCESS. Thank you for your attention to this matter!" Alexis Keenan is a legal reporter for Yahoo Finance. Follow Alexis on X @alexiskweed. Click here for in-depth analysis of the latest stock market news and events moving stock prices Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25 minutes ago
- Yahoo
CoreWeave Gets Citi Lift Ahead Of Q2
Nvidia (NASDAQ:NVDA)-backed CoreWeave (NASDAQ:CRWV) shot higher after Citi upgraded it to Buy from Hold, keeping a $160 target and saying the demand picture finally looks healthier ahead of its August 11 Q2 report. Tyler Radke pointed to rising capex from Microsoft (MSFT)which made up 72% of Q1 revenueas the backbone of his stronger fundamental view and closed a 90-day negative catalyst watch after the stock had fallen 45% from its peak. Warning! GuruFocus has detected 5 Warning Signs with NVDA. CoreWeave is the first cloud provider to deploy Nvidia's Blackwell Ultra GPUs, and that tech momentum helped fuel the rally even as the stock has slid 37% over the past month; it's still up about 157% from its $40 IPO price. Wall Street expects a loss per share of $0.23 on $1.08 B revenue for Q2, and Radke thinks the company's noncancellable contracts with roughly 4-year average durations give better near-term revenue visibility, setting the stage for potential beats and guidance raises. He calls CRWV a leader in GPU-as-a-Service with upside from verticalization up the software stack, but flags the flip side: limited trading history and heavy customer concentration make it high risk and prone to volatility. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
